Navigation Links
New method may allow personalized clinical trial for cancer therapies
Date:8/13/2012

A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy and may offer a way to further refine personalized cancer treatments.

The approach, developed by investigators at Vanderbilt-Ingram Cancer Center, shows that erlotinib a targeted therapy that acts on a growth factor receptor mutated in some lung, brain and other cancers doesn't simply kill tumor cells as was previously assumed. The drug also causes some tumor cells to go into a non-dividing (quiescent) state or to slow down their rate of division. This variability in cell response to the drug may be involved in cancer recurrence and drug resistance, the authors suggest.

The new tool, reported Aug. 12 in Nature Methods, may offer ways to improve personalized cancer therapy by predicting tumor response and testing combinations of targeted therapies in an individual patient's tumor.

In the personalized approach to cancer treatment, a patient's tumor is analyzed for a set of mutations to which there are matching drugs that act on those mutations.

This approach has worked rather well for many cancers that carry specific mutations, said senior author Vito Quaranta, M.D., professor of Cancer Biology.

"The genetics is well understood, the clinical effect is understood and the chemistry behind the therapy is understood. But there is a missing piece," said Quaranta. "Believe it or not, what is actually not understood is how cells respond to these drugs, what is actually happening."

The prevailing view has been that targeted therapies kill all the cells harboring a particular mutation.

But even if the tumor is composed entirely of genetically identical cells which is unlikely a drug will not affect all cells the same way, Quaranta explained.

"Some of these cells may die, some may just stop dividing and sit there (called quiescence), and some may keep dividing, but more slowly."

However, no current tests can provide an accurate, detailed picture of cell behavior needed to understand tumor response to drugs.

So, the investigators, led by first author Darren Tyson, Ph.D., research assistant professor of Cancer Biology, combined powerful automated, time-lapse microscopy with analytical tools and software they developed.

Using these techniques, they could capture the behavior of lung cancer cells every six to 10 minutes for up to 10 days.

As they expected, the targeted therapy erlotinib killed some cells, while others became quiescent. They observed that the drug even affected genetically identical cells (cells that arose from the same parental cell) differently.

"These cells are clearly genetically identical, as identical as they can possibly be because one cell just divided into two, but you get completely different responses: one dies and the other one doesn't," said Tyson. "This suggests that there are other things besides genetics that have to be taken into account."

What those other factors are remains unclear, but the investigators are conducting follow- up experiments to determine what might underlie this differential response.

"And presumably, it is those (quiescent) cells that ultimately result in tumor recurrence," said Tyson.

Quaranta and colleagues hope to take the technology into small clinical trials to test whether it can predict a patient's response to therapy.

"We think that we might be able to forecast what the response is going to be," Quaranta said. "We can take samples from the tumor, subject them to this assay, and since we're looking at response over time, we will have a rate of response."

This could tell oncologists how long a patient's tumor will respond to a given therapy before it recurs. Such information could also help determine which patients will require more aggressive treatment and Quaranta believes the assay will be able to test combinations of drugs on a patient's tumor cells to find the right combination to induce a response.

"We're hoping that this assay or some implementation of this assay will eventually work like a personalized clinical trial," Quaranta said.


'/>"/>

Contact: Melissa Stamm
melissa.stamm@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Study: Methodology of determining financial viability of social security
2. New method to find novel connections from gene to gene, drug to drug and between scientists
3. Newer technology to control blood sugar works better than conventional methods
4. Study suggests new screening method for sudden death in athletes
5. Meditation Method a Matter of Taste
6. New Stanford method enables sequencing of fetal genomes using only maternal blood sample
7. Electronic data methods research seeks to build a learning health care system
8. New delivery method improves efficacy of 2 common Parkinsons disease medications
9. Quick-Reversal Method May Be at Hand for New Blood Thinner
10. Safer Grilling Methods Might Cut Cancer Risk
11. Hear to see: New method for the treatment of visual field defects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Atlanta, Georgia (PRWEB) , ... January 19, 2017 ... ... Reconstructive Surgeons hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of ... latest advancements in breast surgery. Covering topics from cosmetic breast augmentation ...
(Date:1/18/2017)... , ... January 18, 2017 , ... A recent video ... a global discussion about the benefits of fidgeting to relieve stress and anxiety. ... Daniel. Their Think Ink Pen had just completed a successful Kickstarter campaign raising ...
(Date:1/18/2017)... LAUDERDALE, FL (PRWEB) , ... January 18, 2017 ... ... how to manage it from the number one doctor-recommended OTC antiperspirant, Certain Dri. ... and often go untreated. , Certain Dri created this infographic to explain the ...
(Date:1/18/2017)... NJ (PRWEB) , ... January ... ... the specialty pharmacy industry’s leading journal and most-read publication among specialty pharmacists ... University Medical Center through its Strategic Alliance Partnership (SAP) program, announced Brian ...
(Date:1/18/2017)... ... 18, 2017 , ... PrideStaff, a national, franchised staffing ... Paula Turner Pizarro, was recently featured on Fox Business Network's Worldwide Business with ... business leaders from across the globe, provides viewers an opportunity to find solutions ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 /PRNewswire/ ... Research, titled, "Breast Imaging Technologies Market by Type: Global Opportunity ... imaging technologies market size was valued at $2,544 million in ... growing at a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in ...
(Date:1/18/2017)... Jan. 18, 2017   Regenicin, Inc. (OTC ... specializing in the development and commercialization of regenerative cell ... organs, recently reported the Company,s operating results for 2016 ... As the Company described in its recent 10-K ... of substantial accomplishments. The Company,s contract laboratory completed its ...
Breaking Medicine Technology: